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Abstract  Because  of  its  excellent  sensitivity  and  speciﬁcity  to  diagnose  arterial  ischemic
stroke (AIS)  in  the  acute  phase,  MRI  answers  the  main  questions  to  guide  treatment  in
‘‘candidates’’  for  thrombolysis.  It  lasts  less  than  ten  minutes,  can  conﬁrm  the  diagnosis  of
AIS and  distinguish  it  from  hematomas  and  other  ‘‘stroke  mimics’’.  It  can  identify  the  ischemic
penumbra  (perfusion-diffusion  mismatch),  determine  the  site  of  occlusion  and  provide  progno-
stic information  to  adapt  treatment  in  some  cases  in  which  the  indications  are  poorly  deﬁned.
In light  of  the  most  recent  scientiﬁc  ﬁndings,  MRI  can  guide  the  treatment  turning  it  into  thePerfusion-weighted
imaging
investigation  of  choice  in  ‘‘candidates’’  for  thrombolysis.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Clinical  studies  showing  the  effectiveness  of  intravenous  (IV)  rt-PA  (recombinant  tissue
plasminogen  activator)  in  arterial  ischemic  stroke  (AIS)  have  selected  patients  based  on
brain  CT.  In  this  case  the  purpose  of  imaging  was  to  exclude  an  intracranial  hemorrhagic
lesion.  The  NINDS  [1]  study,  the  princeps  IV  thrombolysis  study,  was  published  in  1995  and
many  improvements  have  been  made  in  imaging  since  then.  Currently,  more  sophisticated
imaging  is  often  preferred  to  select  candidates  for  thrombolysis.The  French  National  Health  Authority  guidelines  published  in  May  2009  [2]  on  the  man-
agement  of  AIS  in  the  acute  phase  state:  ‘‘patients  suspected  of  having  acute  AIS  must
have  priority  access  (24/24  h  7/7  d)  to  cerebral  imaging  [.  . .]. MRI  is  the  best  investigation
to  show  early  signs  of  ischemia  and  visualize  intracranial  hemorrhage.  This  should  be
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erformed  as  the  ﬁrst  line  examination.  If  MRI  is  available
s  a  ﬁrst  line  investigation  it  should  be  accessible  in  the
mergency  settings  and  short  protocols  should  be  preferred
.  .  .].  If  urgent  access  to  MRI  is  not  available,  a  cerebral  CT
hould  be  performed’’.
These  guidelines  stress  the  importance  of  accessibility
nd  speed  of  MRI,  which  are  the  prerequisite  conditions,
n  order  to  avoid  delaying  intravenous  thrombolytic  ther-
py.  Rapid  MRI  sequences  (PROPELLER,  Echo  planar),  which
re  of  slightly  poorer  quality  compared  to  the  images  used
n  other  situations,  can  reduce  the  length  of  the  investiga-
ion  consistent  with  the  adage  ‘‘time  is  brain’’  [3]. MRI  can
herefore  be  performed  without  delaying  patient  care.  The
nvestigation  protocol  lasts  between  ﬁve  and  ten  minutes
nd  covers  the  entire  brain  without  radiation.  Patient  agita-
ion  may  deteriorate  image  quality  although  the  information
btained  is  often  sufﬁcient  for  treatment  decision  (Fig.  1).
nly  10—15%  of  patients  therefore  cannot  access  MRI  (severe
gitation,  unstable  hemodynamics  or  contra-indication)  [4].
Some  information  provided  by  MRI  are  essential  whereas
thers  await  validation,  apart  from  some  speciﬁc  situations
>  4.5  h,  age  over  80  years  old,  unknown  time  of  onset,  etc.).
The  purposes  of  MRI  are  listed  below:
Primary  objectives:
to  exclude  hematoma;
to conﬁrm  the  positive  diagnosis  of  AIS;
to  exclude  differential  diagnoses.
Secondary  objectives:
to  characterize  the  infarction;
to date  the  infarction;
to  assess  the  ‘‘core’’  of  the  infarction  (necrosis);
to  establish  the  site  of  occlusion  and  collaterality;
to  assess  the  penumbra.
rimary objectives
o exclude hematoman  order  to  exclude  intraparenchymal  hematoma,  the  main
ifferential  diagnosis  from  AIS  [5—8],  MRI  performs  as  well
igure 1. Restless patient during MRI: the diffusion-weighted
mage shows a hyperintensity in the superﬁcial territory of the left
iddle cerebral artery (red arrows); MRA shows ipsilateral carotid
nd middle cerebral artery occlusion (blue arrow); the T2* image
hows no hemorrhagic lesion. This information is sufﬁcient to decide
 treatment intervention.
s
E
C
M
t
a
a
t
F
w
s
‘
n
E
B
i
T
bM.  Tisserand  et  al.
s  CT,  including  during  the  ﬁrst  few  hours  after  the  onset  of
ymptoms.  The  pattern  of  hematoma  in  the  acute  phase  is:
diffusion-weighted  imaging  hyperintensity  and  reduced
apparent  diffusion  coefﬁcient.  These  can  occasionally
be  confused  with  those  of  an  AIS  although  a  hematoma
presents  a  more  heterogeneous  pattern,  with  magnetic
susceptibility  effects  and  a  brighter  diffusion-weighted
hyperintensity  than  an  acute  ischemic  lesion.  This  het-
erogeneous  appearance  is  also  seen  on  the  T1-weighted
image  (performed  as  the  localizing  sequence)  with  a  T1-
weighted  hypointensity  (whereas  a  hyperacute  ischemic
lesion  is  usually  not  seen  on  T1-weighted  sequence)  and
a  leaﬂike  appearance  in  the  periphery;
pronounced  FLAIR  hyperintensitity  (the  FLAIR  hyperinten-
sity  is  unusual  in  ischemic  lesions  before  3  hours);
peripheral  T2*-weighted  hypointensity  consistent  with
the  presence  of  deoxyhemoglobin  (Fig.  2).
Combined  analysis  of  the  different  sequences,  partic-
larly  diffusion-weighted  and  T2*-weighted  images  avoid
issing  the  diagnosis  of  hematoma  which  is  a  contra-
ndication  to  thrombolytic  therapy.
Apart  from  symptomatic  intraparenchymal  hematoma,
he  T2*-weighted  image  may  show  one  or  several  chronic
icrobleeds  (Fig.  3).  These  are  not  seen  on  CT  and  may
e  single  or  multiple,  lying  deeply  (hypertensive  origin),
r  peripherally  (in  that  case  they  are  suggestive  of  amy-
oid  angiopathy  [9]).  In  a  meta-analysis  of  570  patients,
iehler  et  al.  [10]  found  no  additional  risk  of  hemorrhage
rom  thrombolysis  in  patients  with  microbleeds  (it  should
e  noted  that  very  few  patients  had  multiple  microbleeds
n  this  meta-analysis  [10]).  The  issue  of  the  risk  of  hem-
rrhagic  transformation  and/or  cerebral  hemorrhage  after
hrombolysis  in  patients  with  numerous  microbleeds  is  still
nanswered  as  this  population  was  not  represented  in  the
tudy  reported  by  Fiehler  et  al.  A  trend  towards  greater  risk
ppeared  in  a  more  recent  meta-analysis  [11],  although  this
id  not  reach  statistically  signiﬁcance.
T2*-weighted  images  can  also  assess  the  presence  of
emorrhagic  changes  and  is  more  sensitive  than  CT,  clas-
ifying  hemorrhagic  changes  more  severely  according  to  the
CASS  classiﬁcation  [12]  compared  to  CT  [13]  (Fig.  4).
onﬁrming the diagnosis of AIS
RI  can  conﬁrm  the  positive  diagnosis  of  acute  AIS:  hyperin-
ensity  on  the  diffusion-weighted  images,  distributed  within
n  arterial  territory,  with  a  homogeneous  reduction  of  the
pparent  diffusion  coefﬁcient  (Fig.  5).  MRI  is  more  sensitive
han  CT  particularly  in  the  early  phase  of  ischemia  [14].
alse  negatives  however  can  be  seen  with  the  diffusion-
eighted  images:  posterior  cerebral  fossa  lesions,  small
trokes  and  recent  lesions  or  transient  symptoms  [15]. An
‘optimized’’  diffusion-weighted  sequence  can  reduce  the
umber  of  false  negatives  [16]  (Fig.  6).
xcluding the differential diagnoses
ased  on  the  clinical  presentation  or  even  some  imag-
ng  appearances,  a  number  of  diseases  may  mimic  AIS.
hese  differential  diagnoses  (‘‘stroke  mimics’’)  need  to
e  excluded  to  avoid  inappropriate  thrombolysis.  Other
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Figure 2. MRI can distinguish AIS (acute ischemic stroke) from intraparenchymal hemorrhage. Case 1 is a left deep MCA (middle cerebral
artery) AIS: homogenous hyperintensity on diffusion-weighted imaging with reduced ADC (apparent diffusion coefﬁcient), hyperintensity on
the Fluid Attenuated Inversion Recovery (FLAIR) image without T2* hypointensity. Case 2 is a left deep hyperacute hematoma: heterogeneous
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phyperintensity on diffusion-weighted imaging with a peripheral hyp
and hypointense on T2* (red arrows). This is conﬁrmed by an unenh
diseases  may,  for  example,  cause  a  reduction  in  the  appar-
ent  diffusion  coefﬁcient  on  MRI:  a  recent  hematoma,
other  causes  of  cytotoxic  edema  (reversible  posterior
encephalopathy,  severe  venous  cerebral  thrombosis,  infec-
tious  encephalitis)  [17,18]  (Fig.  7),  hypercellular  lesions
(lymphoma,  medulloblastoma)  [19,20]  or  hyperviscosity
(pyogenic  abscess)  [21].  MRI  can  also  correct  the  diag-
nosis  in  some  ‘‘stroke  mimics’’,  which  are  more  difﬁcult
to  identify,  using  a  combination  of  different  sequences.
These  include  for  example,  migraine  aura  or  postictal  edema
[22,23].
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Figure 3. The T2* image is very sensitive to chronic microbleeds. Thr
b: numerous deep bilateral microbleeds (> 10) are present, in a patient w
located peripherally with superﬁcial hemosiderosis: this appearance sugnse collar and a reduced ADC, peripherally hyperintense on FLAIR
d CT.
econdary objectives
o date the infarction
RI  has  been  shown  to  be  able  to  date  an  AIS  of  unknown
ime  of  onset  (for  example  wake-up  strokes)  [24].  The  tem-
oral  change  in  the  diffusion-weighted  image  begins  with  an
arly  diffusion-weighted  hyperintensity  after  arterial  occlu-
ion.  The  ADC  also  decreases  early,  reaching  a  nadir  around
8  hours,  returns  to  normal  towards  the  end  of  the  second
eek  and  then  increases  in  the  chronic  phase  [25].  The  FLAIR
ee different patients: a: a single deep right microbleed is present.
ith chronic hypertension. c: multiple bilateral microbleeds (> 100)
gests amyloid angiopathy.
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Figure 4. Comparison of the T2* image with CT to assess hem-
orrhagic transformation (at 24 h): a punctiform hypointensity is
present on the T2* image in the left lenticulate nucleus (red arrow)
whereas on unenhanced CT no hemorrhagic hyperdensity is seen.
Figure 5. Positive diagnosis of AIS: diffusion-weighted hyperin-
tensity within an arterial territory (dotted red line) with reduced
apparent diffusion coefﬁcient (not shown) and no marked Fluid
Attenuated Inversion Recovery (FLAIR) hyperintensity with occlu-
sion of the right middle cerebral artery on 3D TOF (Time-Of-Flight)
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Figure 7. MRI as a diagnostic tool in 3 patients suspected of hav-
ing an AIS. The sequences used are: diffusion-weighted imaging
with ADC (apparent diffusion coefﬁcient) map and Fluid Attenu-
ated Inversion Recovery (FLAIR) from left to right. a: herpes virus
encephalitis: left temporal diffusion-weighted hyperintensity pre-
dominantly involving the cortex with focally cortico-subcortical
heterogeneously reduced ADC FLAIR hyperintensity with a swollen
appearance of the left temporal lobe. On the right, meningeal
T1-weighted enhancement after gadolinium. b: glial tumor: left
parietal diffusion-weighted hyperintensity predominantly involving
the cortex, with increased ADC, cortico-subcortical FLAIR hyperin-
tensity with an unusual mass effect for an acute ischemic lesion.
On the right the 3D TOF sequence does not show proximal arte-
rial conclusion. c: cerebral venous thrombosis: left fronto-parietalnd a ‘‘susceptibility vessel sign’’ on the T2* image representing
he intraluminal thrombus (red arrows).
mage  is  normal  or  subnormal  in  the  initial  hours  and  then
ubsequently  becomes  positive  (Fig.  8).  Two  situations  can
e  distinguished  based  on  the  ‘‘diffusion/FLAIR’’  mismatch:
a  diffusion-weighted  hyperintensity  with  no  FLAIR  hyper-
intensity,  representing  usually  a  subacute  lesion  (<  4.5  h)
(Fig.  9);
igure 6. Patient presenting with dizziness for 5 hours: the con-
entional diffusion-weighted images show no clear hyperintensity
uggestive of an ischemic lesion. An optimized diffusion-weighted
equence shows multiple punctate cerebellar and brain stem hyper-
ntensities conﬁrming the suspected diagnosis.
diffusion-weighted hyperintensity predominantly involving the cor-
tex with a heterogeneously increased ADC, FLAIR hyperintensity in
the underlying white matter. On the right the sagittal T1-weighted
images after gadolinium show a defect in the superior sagittal sinus
(
s
•
ftop). On T2* (bottom) susceptibility artefact in the superior sagittal
inus and cortical veins consistent with thrombi.
a diffusion-weighted  hyperintensity  with  a pronounced
FLAIR  hyperintensity,  representing  an  older  ischemic
lesion.  In  such  case,  the  time  from  stroke  onset  is  likely
to  be  >  4.5  hours,  although  AIS  <  4.5  hours  may  show  sub-
tle  signal  changes  on  FLAIR.  Its  sensitivity  and  speciﬁcity
to  detect  an  AIS  <  4.5  h  are  however  not  perfect  (55%
and  60%  respectively  on  a  3T  scanner  [26]).  The  pres-
ence  of  a  ‘‘diffusion/FLAIR’’  mismatch  is  currently  used
as  an  inclusion  criterion  into  a  clinical  trial  on  intravenous
thrombolysis  for  wake-up  strokes,  when  by  deﬁnition  the
time  of  onset  is  unknown  [27].
The  FLAIR  sequence  can  therefore  distinguish  recent
rom  semi-recent  or  old  ischemia  [4]  (Fig.  10) and  assess  the
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Figure 8. Temporal change in ischemia on Fluid Attenuated Inversion Recovery (FLAIR) and diffusion-weighted images and apparent
diffusion coefﬁcient (ADC) map; the pink curve shows the changes of ADC, the acute phase being characterized by an early diffusion-
weighted hyperintensity after arterial occlusion. The ADC decreases early to a nadir around 48 hours returning to normal towards the end
of the second week and is then increased in the chronic phase. The FLA
becomes positive.
cerebral  parenchyma  (lacunar  stroke,  leucoaraiosis,  territo-
rial  ischemic  strokes).  These  latter  are  occasionally  better
seen  on  T2-weighted  imaging  for  example  an  Echo  planar
view  (b  =  0  s/mm2)  from  the  diffusion-weighted  sequence.
To assess the ‘‘core’’ of the infarction
The  ‘‘core’’  or  ‘‘irreversible  necrosis’’  is  assessed  as  a  pro-
gnostic  tool.  The  DEFUSE  [28]  and  EPITHET  [29]  studies
deﬁned  a  ‘‘malignant  proﬁle’’  (deﬁned  by  a  diffusion-
weighted  lesion  and/or  perfusion  volume  over  100  mL).
This  proﬁle  is  associated  with  poor  functional  prognosis  at
3  months  and  an  increased  risk  of  bleeding  after  reperfusion
[30].
Figure 9. Fluid Attenuated Inversion Recovery (FLAIR)/diffusion
mismatch: no FLAIR hyperintensity and diffusion-weighted hyperin-
tensity in the right middle cerebral artery territory. This pattern is
suggestive of an ischemic lesion before 4.5 h.
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iIR image is normal or subnormal in the initial hours and thereafter
Another  MRI  approach  to  assess  the  ‘‘core’’  is  the  DWI-
SPECTS  score  (diffusion-weighted  imaging;  Alberta  Stroke
rogram  Early  CT  score)  (Fig.  11).  This  score  can  be
ore  readily  used  in  routine  practice  than  volume  mea-
urement  as  it  provides  a simple  semi-quantitative  visual
core  alternative  to  volumetry  [31]. Large  ischemic  stroke
low  DWI-ASPECTS  score)  represents  an  increased  risk  of
emorrhagic  transformation  after  thrombolysis  [32].  This
onclusion,  however,  is  disputed  by  Olivot  et  al.  [33]  in  a
opulation  of  patients  receiving  early  intra-arterial  treat-
ent,  as  a  high  diffusion  volume  in  this  study  was  not  always
ynonymous  of  poor  outcome.  This  concept  of  a  cut-off  vol-
me  should  therefore  be  adjusted  by  the  time  between  the
nset  of  symptoms  and  MRI.
o determine the site of occlusion
he  3D  Time-of-Flight  MR  angiography  (3D  TOF)  is  a  ﬂow
mage  that  visualizes  the  site  of  occlusion.  However  it  should
e  borne  in  mind  that  failure  to  visualize  an  artery  on  3D  TOF
an  also  represent  severe  slowing  in  an  artery  that  is  nev-
rtheless  patent.  The  occlusion  site  may  have  implications
n  the  decision  to  treat  for  those  cases  that  are  reputed  to
e  poorly  responsive  to  intravenous  therapy  (basilar  occlu-
ion,  T  carotid  occlusion  combining  occlusion  of  the  end  of
he  internal  carotid  artery  and  the  proximal  segments  of
he  anterior  and  middle  cerebral  arteries  for  example)  par-
icularly  in  considering  endovascular  treatment  [34].  These
ssues  however  remain  to  be  solved.
MRA  is  not  the  only  vascular  sequence  in  the  proto-
ol.  A  T2*-weighted  sequence  can  be  used  to  assess  the
ite  of  occlusion  through  an  artefact  described  as  the
‘susceptibility  vessel  sign’’  (SVS)  [35—37]  (Fig.  12).  This  sign
s  extremely  speciﬁc  for  occlusion  of  the  internal  carotid
1140  M.  Tisserand  et  al.
Figure 10. Assessment of the brain parenchyma: Fluid Atten-
uated Inversion Recovery (FLAIR) (a) and diffusion-weighted (b)
images can distinguish a semi-recent ischemic lesion (FLAIR and
diffusion-weighted hyperintensity, red arrow) from an old ischemic
lesion (FLAIR hyperintensity with no diffusion-weighted hyperin-
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Figure 12. ‘‘Susceptibility Vessel Sign’’ or SVS: magnetic suscep-
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The  penumbra  is  the  area  of  reversible  ischemia  [42].  It
F
C
a
vensity, blue arrow) in the same patient. FLAIR image (c) and (d)
howing vascular leucopathy and old lacunar infarcts.
rtery  or  proximal  segment  (M1)  of  the  MCA  [35].  It  is
eported  to  be  associated  with  cardio  embolic  thrombus
38].  Its  relationship  with  thrombus  composition  is  debated
39].  Extension  of  the  thrombus  can  be  scored  semi  quanti-
atively  using  the  ‘‘clot  burden  score’’  [36].
Vascular  occlusion  can  also  be  indirectly  assessed  from
ollaterality  circulation  from  linear  FLAIR  hyperintensities
r
l
n
igure 11. Volume assessment on diffusion-weighted images. a: DWI-A
T score): in each region named by a letter or a letter combined with a 
ffected region: in this case 7 regions are affected: M1, M2, M3, M5, M6,
olume was 164 cm3.ibility artefact on the T2* images in the proximal segment of the
ight middle cerebral artery due to a thrombus.
or  FLAIR  vascular  hyperintensities,  FVH)  (Fig.  13)  that  can
e  seen  in  the  subarachnoid  spaces  [40]. The  FVH  are  seen  in
rterial  occlusion  and  represent  hemodynamic  disturbances.
heir  prevalence  and  prognostic  value  however  are  debated
n  the  literature.  According  to  Legrand  et  al.,  these  abnor-
alities  represent  a  smaller  volume  of  infarction  and  larger
ismatch  volume  [41].
o assess the penumbraeduces  gradually  with  time  from  the  arterial  occlusion
eaving  in  its  place  irreversible  ischemia  if  the  artery  is
ot  recanalized.  This  progressive  decrease  varies  depending
SPECTS (diffusion-weighted imaging; Alberta Stroke Program Early
ﬁgure represents 1 point. One point is subtracted from 10 for each
 L and I (DWI-ASPECTS = 3). b: volumetry: in this case the diffusion
Patient  ‘‘candidate’’  for  thrombolysis:  MRI  is  essential  1141
Figure 13. Fluid Attenuated Inversion Recovery (FLAIR) vascular
hyperintensities or FVH appearing as linear hyperintensities seen in
Figure 15. Cerebral blood ﬂow (CBF) and Tmax maps illustrating
the homogeneous appearance of the Tmax within the white mat-
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cthe subarachnoid spaces (red arrows) indicating slowing ﬂow in the
meningeal collateral vessels.
on  the  occlusion  site,  severity  of  the  occlusion  and  pres-
ence  of  collateral  circulation.  Penumbral  tissue  is  the
target  for  a  possible  revascularization  intervention.  Many
methods  are  available  to  assess  the  penumbra,  the  most
widely  used  being  the  ‘‘perfusion-diffusion  mismatch’’.
Schematically,  the  diffusion-weighted  sequence  shows  the
irreversible  ischemia  or  ‘‘core’’  (without  considering  the
potential  reversibility  of  lesions  on  diffusion-weighted  imag-
ing  [43])  and  the  perfusion-weighted  sequence  detects  the
hypoperfusion  area.  Lesions  that  are  hypoperfused  without
diffusion  hyperintensity  represent  the  penumbra  (Fig.  14).
The  aim  of  this  approach  is  to  increase  the  thrombolysis
time  window,  offering  recanalization  therapy  beyond  4.5  h
to  patients  with  a  penumbra  in  placebo-controlled  random-
ized  trials.  Assessment  of  the  penumbra  volume  can  identify
patients  who  may  beneﬁt  from  treatment.
Figure 14. Perfusion-diffusion mismatch: minimal punctiform
diffusion-weighted hyperintensity in the left superﬁcial middle
cerebral artery territory with larger abnormalities on the Tmax
map. The 3D TOF image shows left proximal middle cerebral artery
occlusion.
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der and the gray matter (hypoperfusion in the left middle cerebral
rtery territory with reduced CBF and increased Tmax).
Whilst  this  technique  is  attractive,  there  is,  however,  no
onsensus  on  the  best  parameter  to  determine  the  severe
ypoperfusion  area.  The  most  widely  used  parameter  at
resent  is  the  Tmax,  which  is  the  time  to  the  peak  of  residual
unction.  This  parameter  presents  the  advantage  of  homoge-
ous  mapping  (there  is  no  difference  in  Tmax  between  the
hite  matter  and  gray  matter  as  opposed  to  the  cerebral
lood  ﬂow  and  cerebral  blood  volume)  (Fig.  15).  This  param-
ter  can  be  calculated  even  with  short  acquisitions  and
equires  an  arterial  input  function  (AIF)  for  deconvolution
44]. It  correlates  well  with  cerebral  blood  ﬂow  values  cal-
ulated  using  PET-CT  (positron  emission  tomography)  [45].
Moreover  there  is  no  consensus  about  the  Tmax  threshold
o  use.  Currently  the  threshold  in  the  most  recent  stud-
es  is  a  Tmax  >  6  s  [46]. Discrepancies  between  studies  exist
n  the  role  of  this  mismatch  in  selecting  candidates  with
oth  positive  results  (mismatch  useful  to  select  patients  to
ndergo  revascularization)  (DIAS  [47],  DEDAS  [48], DEFUSE
28], EPITHET  [29],  DEFUSE  2  [49])  and  negative  results  (DIAS
 [50],  MR  RESCUE  [51]).  New  randomized  trials  are  there-
ore  ongoing.  The  ECASS  4  study  is  a randomized  phase  3
tudy  comparing  IV  thrombolysis  to  placebo  between  4.5  h
nd  9  h  or  in  wake-up  AIS.  The  main  inclusion  criterion  is  a
erfusion-diffusion  mismatch  on  imaging.
Other  mismatch  techniques  are  proposed  to  assess  the
schemic  penumbra:  diffusion/MR  angiography  and  clini-
al/diffusion  [52].
onclusion
RI  can  be  performed  in  the  acute  phase  of  an  AIS  without
elaying  patient  management.  It  serves  different  purposes,
o  conﬁrm  the  diagnosis  of  AIS  and  exclude  a  hematoma.
RI  provides  better  characterization  of  the  infarction  and
schemic  penumbra  and  opens  the  possibility  of  extending
he  treatment  time  window  (>  4h30)  and  adapting  treatment
epending  on  individual  patient  ﬁndings.
TAKE-HOME  MESSAGES
• MRI  is  the  recommended  investigation  by  the  French
National  Health  Authority  (2009).• It should  be  accessible  and  fast.
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• MRI  meets  the  primary  objectives:
◦ excluding  hematoma,
— MRI  =  CT  to  detect  intraparenchymal  hematoma;
◦ conﬁrming  the  positive  diagnosis  of  ischemic
cerebrovascular  accident,
—  diffuse  hyperintensity  in  an  arterial  territory
with  reduced  apparent  diffusion  coefﬁcient;
◦ excluding  differential  diagnoses.
• MRI  meets  the  secondary  objectives  (characterizing
the  infarction):
◦ dating  the  infarction  with  the  FLAIR  diffusion
mismatch,
◦ assessing  the  ‘‘core’’  (necrosis)  by  DWI-ASPECTS
or  volumetry  (prognostic  role),
◦ assessing  the  site  of  occlusion/collaterality,
◦ assessing  the  penumbra.
• MRI  can  guide  treatment  turning  it  into  the
investigation  of  choice  in  ‘‘candidates’’  for
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linical case
his  50-year-old  right-handed  female  patient  developed
phasia  of  unknown  time  of  onset.  An  MRI  was  performed
t  admission  (Fig.  16).
uestions
)  What  is  the  diagnosis?
A.  Multiple  hematomas.
B.  Infarctions  of  different  ages.
C.  Metastases.
D.  Abscess  and  pre-suppurative  lesion.
)  Describe  the  appearances  of  the  different  lesions.
igure 16. MRI performed at admission (aphasia of unknown
ime of onset) from left to right and top to bottom. A diffusion-
eighted sequence with ADC (apparent diffusion coefﬁcient) map,
luid Attenuated Inversion Recovery (FLAIR), T2* and MR 3D Time-
f-Flight (TOF) angiography.M.  Tisserand  et  al.
)  What  does  the  left  posterior  insular  T2*  hypointensity
represent?
)  Should  thrombolysis  be  performed  in  this  patient?
nswers
A)  Infarctions  of  different  ages.
B)  The  ﬁrst  left  periventricular  lesion  displays  a  diffusion-
weighted  hyperintensity  with  decreased  ADC  (apparent
diffusion  coefﬁcient)  representing  cytotoxic  edema
within  an  arterial  territory.  This  is  an  acute  ischemic
lesion  probably  >  4.5  h  because  the  FLAIR  hyperintensity
is  already  clearly  visible.  The  second  cortico-subcortical
right  frontal  lesion  represents  an  older  ischemia  with
moderate  diffusion-weighted  hyperintensity  with  a  high
ADC.
C)  Distal  thrombus  appearing  as  a  punctate  T2*  hypointen-
sity.
)  No:  the  time  of  onset  is  unknown  and  the  most  recent
ischemic  lesion  is  already  frankly  hyperintense  on  FLAIR
images  suggesting  a  lesion  >  4.5  h.  In  addition  there  are
no  signs  of  proximal  vascular  occlusion.
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